Prostate Cancer Progression and Serum SIBLING (Small Integrin Binding N-Linked Glycoprotein) Levels
Abstract
It is the goal of the current research to develop serum measures of a family of proteins that we have termed SIBLINGs (for small integrin binding ligand N-linked glycoproteins) as markers for use in prostate cancer detection and progression by studying a large population of prostate cancer patients, a large normal (cancer-free) population, a population of men with noncancerous prostate disease, and individuals with prostate cancer before, during and after treatment. Blood levels of SIBLING gene family members in normal (n=200) and subjects with diagnosed prostate cancer (n=200) have been measured for most of the five SIBLING proteins. The sensitivity, specificity and predictive value of these markers will be completed once all assays have been finished and the data "secured." Similarly, determining how the levels of SIBLINGs in blood correlate with clinical stage and progression, although underway, requires the completion of each SIBLING assay for all samples. This research will determine whether SIBLING levels in blood (a) have high sensitivity and high specificity for prostate cancer detection, (b) can be measured in a general laboratory setting, and (c) provide useful prognostic information on response to treatment and the likelihood of disease progression.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2005
- Accession Number
- ADA446383
Entities
People
- Neal Fedarko
Organizations
- Johns Hopkins University